Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grifols shrugs off Spanish stock market woes with 49% growth in 2011

This article was originally published in Clinica

Executive Summary

Spanish biosciences group Grifols ended July as the best-performing stock so far this year on Madrid’s IBEX index of 35 leading shares. Its 49.5% share price rise (to €15.24) has taken place against a 2.3% contraction of the index (to 9,630 points) since the end of December 2010. The Barcelona-based group, which specialises in blood products, diagnostics (through its Diagnostic Grifols subsidiary) and hospital supplies, is also the third-best performing IBEX-35 stock over the last 12 months.

You may also be interested in...



Making The Case For A Legislative Deal On Drug Pricing

Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing behind us with a legislative compromise.

NANS 2021: Nevro’s HF10 Spinal-Cord Stimulator Succeeds In Two Trials

SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.

Warning Letter Roundup & Recap – 19 January 2021

No device-related warning letters were released by the US FDA the week of 19 January.

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel